Pharmacogenetic investigation of smoking cessation treatment

Caryn Lerman, Peter G. Shields, E. Paul Wileyto, Janet Audrain, Angela Pinto, Larry Hawk, Shiva Krishnan, Raymond Niaura, Leonard Epstein

Research output: Contribution to journalArticle

Abstract

Despite the efficacy of bupropion for smoking cessation, smokers exhibit variability in treatment outcome. The CYP2B6 gene has been implicated in bupropion kinetics and nicotine metabolism, and is a plausible candidate for pharmacogenetic studies of treatment response. We investigated whether a functional genetic polymorphism in the CYP2B6 gene predicts smoking outcomes in a placebo-controlled randomized trial. Four hundred and twenty-six smokers of European Caucasian ancestry provided blood samples and received bupropion (300 mg/day for 10 weeks) or placebo, plus counseling. Smoking status, abstinence symptoms and side-effects were recorded weekly, and smoking status was verified at the end of treatment and at 6-month follow-up. Smokers with a decreased activity variant of CYP2B6 reported greater increases in cravings for cigarettes following the target quit date and had higher relapse rates. These effects were modified by a significant gender x genotype x treatment interaction, suggesting that bupropion attenuated the effects of genotype among female smokers. We conclude that smokers with the CYP2B6 variant may be more vulnerable to abstinence symptoms and relapse. Bupropion may attenuate these effects, especially among females. Additional trials are warranted to confirm these results, as are studies to explore the neurobiological mechanisms. Such research could ultimately enable practitioners to select the optimal type and dose of medication for individual smokers.

Original languageEnglish (US)
Pages (from-to)627-634
Number of pages8
JournalPharmacogenetics
Volume12
Issue number8
DOIs
StatePublished - Nov 2002

Fingerprint

Bupropion
Withholding Treatment
Pharmacogenetics
Smoking Cessation
Smoking
Genotype
Placebos
Recurrence
Genetic Polymorphisms
Nicotine
Tobacco Products
Genes
Counseling
Therapeutics
Randomized Controlled Trials
Cytochrome P-450 CYP2B6
Research

Keywords

  • Genetics
  • Metabolism
  • Smoking cessation

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., ... Epstein, L. (2002). Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics, 12(8), 627-634. https://doi.org/10.1097/00008571-200211000-00007

Pharmacogenetic investigation of smoking cessation treatment. / Lerman, Caryn; Shields, Peter G.; Wileyto, E. Paul; Audrain, Janet; Pinto, Angela; Hawk, Larry; Krishnan, Shiva; Niaura, Raymond; Epstein, Leonard.

In: Pharmacogenetics, Vol. 12, No. 8, 11.2002, p. 627-634.

Research output: Contribution to journalArticle

Lerman, C, Shields, PG, Wileyto, EP, Audrain, J, Pinto, A, Hawk, L, Krishnan, S, Niaura, R & Epstein, L 2002, 'Pharmacogenetic investigation of smoking cessation treatment', Pharmacogenetics, vol. 12, no. 8, pp. 627-634. https://doi.org/10.1097/00008571-200211000-00007
Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002 Nov;12(8):627-634. https://doi.org/10.1097/00008571-200211000-00007
Lerman, Caryn ; Shields, Peter G. ; Wileyto, E. Paul ; Audrain, Janet ; Pinto, Angela ; Hawk, Larry ; Krishnan, Shiva ; Niaura, Raymond ; Epstein, Leonard. / Pharmacogenetic investigation of smoking cessation treatment. In: Pharmacogenetics. 2002 ; Vol. 12, No. 8. pp. 627-634.
@article{c164b05d1b4b425eab87ced3a37fad3c,
title = "Pharmacogenetic investigation of smoking cessation treatment",
abstract = "Despite the efficacy of bupropion for smoking cessation, smokers exhibit variability in treatment outcome. The CYP2B6 gene has been implicated in bupropion kinetics and nicotine metabolism, and is a plausible candidate for pharmacogenetic studies of treatment response. We investigated whether a functional genetic polymorphism in the CYP2B6 gene predicts smoking outcomes in a placebo-controlled randomized trial. Four hundred and twenty-six smokers of European Caucasian ancestry provided blood samples and received bupropion (300 mg/day for 10 weeks) or placebo, plus counseling. Smoking status, abstinence symptoms and side-effects were recorded weekly, and smoking status was verified at the end of treatment and at 6-month follow-up. Smokers with a decreased activity variant of CYP2B6 reported greater increases in cravings for cigarettes following the target quit date and had higher relapse rates. These effects were modified by a significant gender x genotype x treatment interaction, suggesting that bupropion attenuated the effects of genotype among female smokers. We conclude that smokers with the CYP2B6 variant may be more vulnerable to abstinence symptoms and relapse. Bupropion may attenuate these effects, especially among females. Additional trials are warranted to confirm these results, as are studies to explore the neurobiological mechanisms. Such research could ultimately enable practitioners to select the optimal type and dose of medication for individual smokers.",
keywords = "Genetics, Metabolism, Smoking cessation",
author = "Caryn Lerman and Shields, {Peter G.} and Wileyto, {E. Paul} and Janet Audrain and Angela Pinto and Larry Hawk and Shiva Krishnan and Raymond Niaura and Leonard Epstein",
year = "2002",
month = "11",
doi = "10.1097/00008571-200211000-00007",
language = "English (US)",
volume = "12",
pages = "627--634",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Pharmacogenetic investigation of smoking cessation treatment

AU - Lerman, Caryn

AU - Shields, Peter G.

AU - Wileyto, E. Paul

AU - Audrain, Janet

AU - Pinto, Angela

AU - Hawk, Larry

AU - Krishnan, Shiva

AU - Niaura, Raymond

AU - Epstein, Leonard

PY - 2002/11

Y1 - 2002/11

N2 - Despite the efficacy of bupropion for smoking cessation, smokers exhibit variability in treatment outcome. The CYP2B6 gene has been implicated in bupropion kinetics and nicotine metabolism, and is a plausible candidate for pharmacogenetic studies of treatment response. We investigated whether a functional genetic polymorphism in the CYP2B6 gene predicts smoking outcomes in a placebo-controlled randomized trial. Four hundred and twenty-six smokers of European Caucasian ancestry provided blood samples and received bupropion (300 mg/day for 10 weeks) or placebo, plus counseling. Smoking status, abstinence symptoms and side-effects were recorded weekly, and smoking status was verified at the end of treatment and at 6-month follow-up. Smokers with a decreased activity variant of CYP2B6 reported greater increases in cravings for cigarettes following the target quit date and had higher relapse rates. These effects were modified by a significant gender x genotype x treatment interaction, suggesting that bupropion attenuated the effects of genotype among female smokers. We conclude that smokers with the CYP2B6 variant may be more vulnerable to abstinence symptoms and relapse. Bupropion may attenuate these effects, especially among females. Additional trials are warranted to confirm these results, as are studies to explore the neurobiological mechanisms. Such research could ultimately enable practitioners to select the optimal type and dose of medication for individual smokers.

AB - Despite the efficacy of bupropion for smoking cessation, smokers exhibit variability in treatment outcome. The CYP2B6 gene has been implicated in bupropion kinetics and nicotine metabolism, and is a plausible candidate for pharmacogenetic studies of treatment response. We investigated whether a functional genetic polymorphism in the CYP2B6 gene predicts smoking outcomes in a placebo-controlled randomized trial. Four hundred and twenty-six smokers of European Caucasian ancestry provided blood samples and received bupropion (300 mg/day for 10 weeks) or placebo, plus counseling. Smoking status, abstinence symptoms and side-effects were recorded weekly, and smoking status was verified at the end of treatment and at 6-month follow-up. Smokers with a decreased activity variant of CYP2B6 reported greater increases in cravings for cigarettes following the target quit date and had higher relapse rates. These effects were modified by a significant gender x genotype x treatment interaction, suggesting that bupropion attenuated the effects of genotype among female smokers. We conclude that smokers with the CYP2B6 variant may be more vulnerable to abstinence symptoms and relapse. Bupropion may attenuate these effects, especially among females. Additional trials are warranted to confirm these results, as are studies to explore the neurobiological mechanisms. Such research could ultimately enable practitioners to select the optimal type and dose of medication for individual smokers.

KW - Genetics

KW - Metabolism

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=12244267745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244267745&partnerID=8YFLogxK

U2 - 10.1097/00008571-200211000-00007

DO - 10.1097/00008571-200211000-00007

M3 - Article

VL - 12

SP - 627

EP - 634

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 8

ER -